Analyst Insights - Digital Health Posts
Read our Analysts’ insights and expert opinions on the latest healthcare technology industry developments and market trends. Signify Research provides both free insights and premium insights which are only available to subscribers of "Signify Premium Insights".
Click on the premium insights link below to filter for just the premium content.

Signify Premium Insight: MRI and Meeting the Need for Better Imaging
Signify Premium Insights Subscription Required
24th November 2022 – This Premium Insight sees Medical Imaging Research Manager, Bhvita Jani, detail some of the key findings in Signify Research’s MRI Equipment – World – 2022 report.

Signify Premium Insight: Ask the Analyst: Steep Learning Curve for Global RPM Community
Signify Premium Insights Subscription Required
24th November 2022 – The global RPM industry is still in its formative stages, with multiple barriers limiting adoption to date, says Gareth Jones, Senior Analyst and Lead Author of Signify Research’s first stand-alone global Remote Patient Monitoring Report.

Sustainability and MDR: The Catalysts Sparking Change in Market Development and Innovation
Device regulations are imperative for the quality and safety of medical care by ensuring patients are not exposed to harmful products. As such, medical regulatory bodies are focused on mitigating the risk of patient harm and ensuring the safety of devices used in treatment. In May 2021, the Medical Device Regulation (MDR) came into force leading to subsequent impacts on the legislative requirements of medical devices sold to the European Union.

Clinical Data: How to Approach Monetisation for Real-World Use
23rd November – In this insight, we discuss the BioTechX conference in Basel and what the conference’s discourse revealed about cRWD and it’s potential over the next few years.

Signify Premium Insight: Amazon in Prime Position with HealthLake Plans
Signify Premium Insights Subscription Required
22nd November 2022 – Amazon, like several of its Big Tech peers, has redoubled its efforts in medical imaging. The Seattle-based firm makes some bold claims, but will they be enough to win custom away from its rivals?